Precision Medicine and Diagnostics

Since the completion of the Human Genome Project in 2003, stakeholders across the US healthcare system have worked to advance precision medicine. Today, diagnostic technologies like next-generation-sequencing (NGS) offer both dazzling possibilities and questions on how to assess these technologies’ quality and value. 

Tapestry has extensive experience bringing leaders together to address issues in NGS and genomics, diagnostics innovation, and quality assurance.

Projects include: 

• The Diagnostic Quality Assurance Pilot & Related Initiatives: We sought a new approach to ensure that molecular diagnostics accurately and consistently inform therapy selection. Learn more about Tapestry’s work on the pilot and related initiatives here.

• Multicancer Early Detection Initiative: MCED technologies, which aim to identify early signals of cancer, signal a new era in cancer screening and prevention, but their introduction into the market faces complexities. Tapestry engaged diverse stakeholders to tackle concerns around MCED adoption. This work laid the foundation for a new independent organization—the MCED Consortium—to address these issues on a long-term basis.

• The Sustainable Predictive Oncology Therapeutics and Diagnostics (SPOT/Dx) Working Group:This multistakeholder platform addressed the advent of precision medicine and innovative diagnostics, covering issues ranging from reimbursement policy for laboratory tests to proficiency testing. Learn more about SPOT/Dx here and here. 

• The Diagnostics Innovation Network: DxIN brought together health and life insurers with genomics experts and others to address the widespread growth of genomics—not only in the clinic but also via direct-to-consumer models—and its application for patients and the general public.